Valerio Therapeutics Société anonyme (0NWK.L)
- Previous Close
0.2725 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.3520 - Volume
0 - Avg. Volume
3,365 - Market Cap (intraday)
69,444 - Beta (5Y Monthly) 1.63
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
valeriotx.com39
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0NWK.L
Performance Overview: 0NWK.L
Trailing total returns as of 4/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0NWK.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0NWK.L
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.50%
Return on Equity (ttm)
-74.37%
Revenue (ttm)
1.44M
Net Income Avi to Common (ttm)
-19.73M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
16.83M
Total Debt/Equity (mrq)
58.64%
Levered Free Cash Flow (ttm)
-9.61M
Company Insights: 0NWK.L
0NWK.L does not have Company Insights